Immunotherapy plus chemo for relapsed small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether a combination of two immunotherapy drugs (toripalimab and JS004) plus chemotherapy can help control relapsed or extensive-stage small cell lung cancer. It is designed for people whose cancer has spread or returned and who are generally healthy enough to receive strong treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have small cell lung cancer that has spread or come back after initial treatment.
- You must be at least 18 years old.
- You must be well enough to be up and about (ECOG score 0 or 1).
- You must have at least one tumor that can be measured on a scan.
- You should not have another active cancer or serious health problems, such as uncontrolled high blood pressure or a severe heart condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs (toripalimab and JS004) to standard chemotherapy before surgery can help shrink limited-stage small cell lung cancer. The goal is to find better ways to treat this cancer before surgery.
This trial tests whether a combination of toripalimab (an immunotherapy drug) and chemotherapy can help prevent small cell lung cancer from coming back after surgery. It is for people who had an unexpected finding of small cell lung cancer after their tumor was removed.
This trial tests a combination of the immunotherapy drug toripalimab with standard chemotherapy for people with advanced small cell lung cancer that has gotten worse after previous treatments. It aims to see if this combination can help control the cancer.
This study tests a combination of two drugs (BL0020 and Toripalimab) in patients whose small cell lung cancer has come back after initial chemotherapy treatment. The goal is to see if this combination is safe and can help control the cancer.
This trial tests combining standard chemotherapy with radiation (chemoradiotherapy) plus two additional drugs, toripalimab and surufatinib, for people with limited-stage small cell lung cancer. The goal is to see if this combination improves outcomes.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.